Abbott received FDA approval for an expanded indication for its Deep Brain Stimulation system, to include targeting of internal globus pallidus. The GPi plays an integral role in the motor function. When targeted with DBS, Parkonson’s symptoms not adequately controlled by medication can improve.
The directed stimulation system is now approved for all major targets used to treat movement disorders, using an iOS software platform and Bluetooth.
The company’s PROGRESS study is the largest DBS study for directional lead use in Parkinson’s disease.
Abbott’s Erika Ross will discuss advanced neurmodulation technologies at ApplySci’s Wearable Tech + Digital Health + Neurotech Silicon Valley conference on February 11-12, 2020